Floatz logo

Topamax

Cannabis-Related Disorder

University of CincinnatiPhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
53/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Cannabis-Related Disorder cohort.

Asset / SponsorPhaseRating
Clozapine
Dartmouth-Hitchcock Medical Center
Phase 4BB
Risperdal
Dartmouth-Hitchcock Medical Center
Phase 4BB
Seroquel®
University of Cincinnati
Phase 4BB
Metformin
Nova Scotia Health Authority
Phase 4BB
Tirzepatide
McMaster University
Phase 3B

View all 15 →

Same molecule, other indications

Topamax is also rated in:

focal epilepsyDormant
A
Indicative ·
80 / 100
View asset →
migraine without auraDormant
BBB
Indicative ·
78 / 100
View asset →
migraine with auraDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →